Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tarsus Pharmaceuticals (TARS)
NASDAQ:TARS
RESEARCH TOOLSreports
Tarsus Pharmaceuticals (TARS) Stock Price & Analysis
160 Followers
TARS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.57 - $42.50
Previous Close$27.55
Volume406.63K
Average Volume (3M)636.88K
Market Cap
$1.04B
Enterprise Value$843.26M
Total Cash (Recent Filing)$227.44M
Total Debt (Recent Filing)$29.82M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Aug 08, 2024EPS Estimate
-$0.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.77
Shares Outstanding37,781,693
10 Day Avg. Volume747,710
30 Day Avg. Volume636,881
Standard Deviation0.19
R-Squared0.08
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)5.10
Price to Sales (P/S)56.48
Price to Cash Flow (P/CF)-6.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue48.33
Enterprise Value/Gross Profit53.19
Enterprise Value/Ebitda-8.64
Forecast
1Y Price Target
$57.67Price Target Upside99.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Tarsus Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceTarsus reported strong 1Q results with sales of Xdemvy meaningfully outperforming expectations.
Market PotentialA retrospective study conducted in the US suggests ~58% of patients visiting eye care clinics have collarettes, a pathognomonic sign of DB, which speaks to the size of the potential market.
Product LaunchTarsus’ launch of XDEMVY for demodex blepharitis (DB) continues to dramatically outperform expectations, proving one of the fastest non-orphan specialty pharma launches in recent memory.
Bears Say
Payor CoverageIssues with payor coverage and patient access were frequently cited by those who rated Xdemvy lower.
Regulatory UncertaintyThere is curiosity about what endpoint(s) the FDA will ultimately align on for larger pivotal studies.
Study LimitationsResults are limited by the absence of a vehicle comparator, raising questions about the study’s robustness.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TARS FAQ
What was Tarsus Pharmaceuticals’s price range in the past 12 months?
Tarsus Pharmaceuticals lowest stock price was $12.57 and its highest was $42.50 in the past 12 months.
What is Tarsus Pharmaceuticals’s market cap?
Currently, no data Available
When is Tarsus Pharmaceuticals’s upcoming earnings report date?
Tarsus Pharmaceuticals’s upcoming earnings report date is Aug 08, 2024 which is in 36 days.
How were Tarsus Pharmaceuticals’s earnings last quarter?
Tarsus Pharmaceuticals released its earnings results on May 08, 2024. The company reported -$1.01 earnings per share for the quarter, beating the consensus estimate of -$1.181 by $0.171.
Is Tarsus Pharmaceuticals overvalued?
According to Wall Street analysts Tarsus Pharmaceuticals’s price is currently Undervalued.
Does Tarsus Pharmaceuticals pay dividends?
Tarsus Pharmaceuticals does not currently pay dividends.
What is Tarsus Pharmaceuticals’s EPS estimate?
Tarsus Pharmaceuticals’s EPS estimate is -$0.93.
How many shares outstanding does Tarsus Pharmaceuticals have?
Tarsus Pharmaceuticals has 37,781,693 shares outstanding.
What happened to Tarsus Pharmaceuticals’s price movement after its last earnings report?
Tarsus Pharmaceuticals reported an EPS of -$1.01 in its last earnings report, beating expectations of -$1.181. Following the earnings report the stock price went down -8.862%.
Which hedge fund is a major shareholder of Tarsus Pharmaceuticals?
Among the largest hedge funds holding Tarsus Pharmaceuticals’s share is Perceptive Advisors LLC. It holds Tarsus Pharmaceuticals’s shares valued at 47M.
---
Tarsus Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.67 (99.34% Upside)
$57.67 (99.34% Upside)
Blogger Sentiment
Bullish
TARS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 159.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.46%
12-Months-Change
Fundamentals
Return on Equity
-66.07%
Trailing 12-Months
Asset Growth
65.37%
Trailing 12-Months
Company Description
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites.
---
TARS Earnings Call
Q1 2024
0:00 / 0:00
---
TARS Stock 12 Month Forecast
Average Price Target
$57.67
▲(99.34% Upside)
Technical Analysis
uniQure
―
Crispr Therapeutics AG
―
Editas Medicine
―
Intellia Therapeutics
―
Voyager Therapeutics
―
Best Analysts Covering TARS
1 Year
1 Year Success Rate
6/8 ratings generated profit
1 Year Average Return
+49.26%
reiterated a buy rating 2 months ago
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +49.26% per trade.
---